Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Squamous Cell Carcinoma of Head and Neck 14Head and Neck Neoplasms 11Glioblastoma 8Prostatic Neoplasms 7Carcinoma 6Rectal Neoplasms 5Pancreatic Neoplasms 5Gliosarcoma 5Carcinoma, Non-Small-Cell Lung 5Astrocytoma 5Neoplasm Metastasis 4Uterine Cervical Neoplasms 3Neoplasms 3Glioma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Oligodendroglioma 2Medulloblastoma 2Lymphoma, Follicular 2Lymphoma 2Liver Neoplasms 2Leukemia, Myeloid, Acute 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Esophageal Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1

Interventions

Cyclophosphamide 17fludarabine 16fludarabine phosphate 11venetoclax 9Azacitidine 9Rituximab 8Nivolumab 7Melphalan 7Tacrolimus 6Cytarabine 6Specimen Handling 5Sirolimus 5Ipilimumab 5Clofarabine 5CTLA-4 Antigen 5Antilymphocyte Serum 5belinostat 4aldesleukin 4Thiotepa 4Standard of Care 4Practice Guidelines as Topic 4Mycophenolic Acid 4Methotrexate 4Magnetic Resonance Spectroscopy 4Interleukin-2 4Granulocyte Colony-Stimulating Factor 4Dexamethasone 4Busulfan 4Bortezomib 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hematologic Neoplasms × Radiotherapy, Intensity-Modulated × Clear all
NCT02333162 2026-03-30

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

University of Chicago

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡